Levodopa/Carbidopa/Entacapone Rivopharm

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Rivopharm, is an antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease and motor fluctuations in patients with Parkinson's disease.

GNH USA supplies Levodopa/Carbidopa/Entacapone Rivopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson’s disease and related motor complications.

- Parkinson's disease: improves motor symptoms by increasing central dopamine levels. - Motor fluctuations in Parkinson's disease: reduces "off" time and smooths response to therapy. - Early-stage Parkinson's disease adjunct: used as part of initial therapy to delay symptom progression.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Orthostatic hypotension: drop in blood pressure upon standing. - Dyskinesia: involuntary movements, often dose‑related.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and rigidity. - Severe depression or suicidal thoughts: may emerge or worsen. - Cardiac arrhythmias: uncommon but possible, especially with pre‑existing heart disease.

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures.

- Renal impairment: dose may need adjustment; monitor renal function. - Hepatic disease: use with caution; liver function tests recommended. - History of melanoma or skin cancer: monitor for new lesions. - Concomitant MAO‑B inhibitors: avoid concurrent use to prevent hypertensive crisis. - Pregnancy and breastfeeding: safety not established; weigh risks and benefits. - Store at ambient temperature: keep below 25 °C, protect from moisture in original container.

Levodopa/Carbidopa/Entacapone interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish antiparkinson effect. - High‑dose pyridoxine (vitamin B6): reduces levodopa conversion.

Moderate Interactions (Monitor Closely): - Iron or calcium supplements: decrease levodopa absorption; separate dosing by at least 2 hours. - Antihypertensive agents: additive blood pressure lowering. - SSRIs or SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.